StockWatch
·

Concord Drugs Ltd Q4 FY26 Results

CONCORDQ4 FY26 Results
Filing
MetricValue ( Cr)Q3 FY26Q4 FY25
Revenue37.89123.3%264.6%
Total Income37.90123.1%264.5%
Expenditure37.15122.6%259.4%
PBT0.75152.4%1189.0%
Net Profit0.53143.3%1253.8%
OPM3.92%1.51pp6.11pp
NPM1.39%0.11pp1.01pp
EPS0.47193.8%1075.0%
View full financials

Informational and educational content only. Not investment advice.